About Us
About Phio
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) is a clinical stage biotechnology company whose proprietary INTASYL™ RNAI technology makes immune cells more effective in killing tumor cells. INTASYL is the only self-delivering RNAi technology focused on immuno-oncology therapeutics. INTASYL drugs precisely target specific proteins that reduce the body’s ability to fight cancer, without the need for specialized formulations or drug delivery systems.
Leadership

Robert Bitterman
President & Chief Executive Officer

Linda Mahoney
VP of Project Development

Caitlin Kontulis
VP of Finance and Administration

Jim Cardia, Ph.D.
VP of Scientific Operations
Board of Directors

Robert Bitterman
Chairman

Patricia A. Bradford
Director

Geert Cauwenbergh, Dr.Med.Sc.
Director

Robert Ferrara
Director

Jonathan Freeman, Ph.D.
Director

Curtis Lockshin, Ph.D.
Director
Scientific Advisory Board

James D. Griffin, M.D.

Rolf Kiessling, M.D., Ph.D.

Pamela Pavco, Ph.D.